In Vitro Properties of a High Affinity Selective Antagonist of the VIP1 Receptor

Gourlet, P., P. De Neef, J. Cnudde, M. Waelbroeck and P. Robberecht. In vitro properties of a high affinity selective antagonist of the VIP₁ receptor. Peptides 18(10) 1555–1560, 1997.—A selective high affinity VIP₁ receptor antagonist [Acetyl-His¹, D-Phe², Lys¹⁵, Arg¹⁶, Leu¹⁷] VIP(3-7)/GRF(8-27) or PG 97-269 was synthesized, by analogy with recently obtained selective VIP₁ receptor agonists. The properties of the new peptide were evaluated on Chinese hamster ovary (CHO) cell membranes expressing either the rat VIP₁-, rat VIP₂- or the human VIP₂- recombinant receptors and on LoVo cell membranes expressing exclusively the human VIP₁ receptor. The IC₅₀ values of ¹²⁵I-VIP binding inhibition by PG 97-269 were 10, 2000, 2 and 3000 nM on the rat VIP₁-, rat VIP₂-, human VIP₁- and human VIP₂ receptors, respectively. PG 97-269 had a negligible affinity for the PACAP I receptor type. It did not stimulate adenylate cyclase activity, but inhibited competitively effect of VIP on the VIP₁ receptor mediated stimulation of adenylate cyclase activity. The K_i values were respectively of 15 ± 5 nM and 2 ± 1 nM for the rat and human VIP₁ receptors. Thus the described molecule in the first reported VIP antagonist with an affinity in the nM range and with a high selectivity for the VIP₁ receptor subclass. It may be useful for evaluation of the physiological role of VIP in rat and human tissues.     

Contributions of molecular phylogenetics to foraminiferal taxonomy: General overview and example of Pseudoeponides falsobeccarii

Molecular phylogenetics gives new insights into the taxonomy of foraminifera, independent of their morphology. After a survey of the present knowledge on how molecular phylogeny can contribute to foraminiferal taxonomy, we present an applied example. The comparison of ribosomal DNA (rDNA) sequences belonging to the SSU (Small Subunit) and LSU (Large Subunit) genes of Pseudoeponides falsobeccarii with other similar sequences of rotaliids available in GenBank shows that this species actually belongs to the genus Ammonia, because it groups inside the other Ammonia sequences instead of forming a distinct clade. Moreover, Ammonia falsobeccarii forms a clade well separated from other Ammonia phylotypes, meaning that it can be considered as a distinct species, and not as an ecophenotype of one of the other Ammonia species.     

Advances and challenges in gene‐based approaches for osteoarthritis

Osteoarthritis (OA), a paramount cause of physical disability for which there is no definitive cure, is mainly characterized by the gradual loss of the articular cartilage. Current nonsurgical and reconstructive surgical therapies have not met success in reversing the OA phenotype so far. Gene transfer approaches allow for a long‐term and site‐specific presence of a therapeutic agent to re‐equilibrate the metabolic balance in OA cartilage and may consequently be suited to treat this slow and irreversible disorder. The distinct stages of OA need to be respected in individual gene therapy strategies. In this context, molecular therapy appears to be most effective for early OA. A critical step forward has been made by directly transferring candidate sequences into human articular chondrocytes embedded within their native extracellular matrix via recombinant adeno‐associated viral vectors. Although extensive studies in vitro attest to a growing interest in this approach, data from animal models of OA are sparse. A phase I dose‐escalating trial was recently performed in patients with advanced knee OA to examine the safety and activity of chondrocytes modified to produce the transforming growth factor β1 via intra‐articular injection, showing a dose‐dependent trend toward efficacy. Proof‐of‐concept studies in patients prior to undergoing total knee replacement may be privileged in the future to identify the best mode of translating this approach to clinical application, followed by randomized controlled trials. Copyright © 2013 John Wiley & Sons, Ltd.     

Interspecies variation of Kitasatospora recifensis endophytic from yam bean producing thermostable amylases in alternative media

An endophytic actinomycete isolated from tubers of yam beam (Pachyrhizus erosus L. Urban) was classified as a novel species nominated Kitasatospora recifensis based in phenotypic and genotypic analysis (16S rDNA gene sequence). Monosporic culture using specific ISP2 media revealed three interspecies, which were identified by DNA southern hybridization (Wild strain 13817 W, Aerial Mycelium strain 13817 AM and Vegetative Mycelium strain 13817 VM). The strains were tested for the production of amylolitic enzymes in alternative media. Maximum yields for both enzymes were observed in starch-casein. Higher α-amylase was obtained with strain 13817 W in starch-urea, and amyloglucosidase with strain 13817 AM in starch-ammonium that are economic sources and may be important for industrial purposes. Type strain (DAUFPE 13817 ^T  = KCTC 9972^T = DSM 44943^T).     

Influence of Menstrual Cycle Phase and Oral Contraceptive Use on the Time-of-Day Effect on Maximal Anaerobic Power

This study was designed to analyse the time-of-day effect in maximal anaerobic power, and the influence of menstrual cycle phase and oral contraceptive use on any diurnal effect. Diurnal variations in maximal cycling power were studied in 11 eumenorrheic women and 10 women using monophasic oral contraceptives. Subjects were tested at 09:00, 14:00 and 18:00 hours, assigned randomly on separate days, in the mid-follicular or pseudo-follicular phase (days 7, 8, 9) and in the mid-luteal or pseudo-luteal phase (days 19, 20, 21) of the menstrual cycle. The order of test sessions was randomly assigned. Body mass was measured before, and rectal temperature after, a standardized 15-min warm-up. Maximal cycling power (Pc) was determined by a force-velocity test. Rectal temperature significantly increased from morning (09:00) to afternoon (14:00 and 18:00) in follicular and luteal phases for eumenorrheic subjects, and in days 7–9 and days 19–21 for contraceptive users (p < 0.05). No significant interaction effects (time of day × group × cycle phase) were observed for rectal temperature. In eumenorrheic subjects, Pc increased significantly from 09:00 to afternoon during the follicular phase (P < 0.05). In contrast, no significant time-of-day effects were observed during the luteal phase in eumenorrheic subjects, and at any cycle phase in contraceptive users. Analysis of variance failed to reveal any significant interaction effects for Pc. This study suggested that the time-of-day effect on maximal anaerobic power could be damped during the luteal phase of eumenorrheic women or at any cycle phase by oral contraceptive use.     

Arp2/3-dependent mechanical control of morphogenetic robustness in an inherently challenging environment

1. Download : Download high-res image (239KB)
2. Download : Download full-size image

     

Targeting sphingosine kinase 1 (SK1) enhances oncogene-induced senescence through ceramide synthase 2 (CerS2)-mediated generation of very-long-chain ceramides

Senescence is an antiproliferative mechanism that can suppress tumor development and can be induced by oncogenes such as genes of the Ras family. Although studies have implicated bioactive sphingolipids (SL) in senescence, the specific mechanisms remain unclear. Here, using MCF10A mammary epithelial cells, we demonstrate that oncogenic K-Ras (Kirsten rat sarcoma viral oncogene homolog) is sufficient to induce cell transformation as well as cell senescence—as revealed by increases in the percentage of cells in the G1 phase of the cell cycle, p21^{WAF1/Cip1/CDKN1A} (p21) expression, and senescence-associated β-galactosidase activity (SA-β-gal). Furthermore, oncogenic K-Ras altered SL metabolism, with an increase of long-chain (LC) C18, C20 ceramides (Cer), and very-long-chain (VLC) C22:1, C24 Cer, and an increase of sphingosine kinase 1 (SK1) expression. Since Cer and sphingosine-1-phosphate have been shown to exert opposite effects on cellular senescence, we hypothesized that targeting SK1 could enhance oncogenic K-Ras-induced senescence. Indeed, SK1 downregulation or inhibition enhanced p21 expression and SA-β-gal in cells expressing oncogenic K-Ras and impeded cell growth. Moreover, SK1 knockdown further increased LC and VLC Cer species (C18, C20, C22:1, C24, C24:1, C26:1), especially the ones increased by oncogenic K-Ras. Fumonisin B1 (FB1), an inhibitor of ceramide synthases (CerS), reduced p21 expression induced by oncogenic K-Ras both with and without SK1 knockdown. Functionally, FB1 reversed the growth defect induced by oncogenic K-Ras, confirming the importance of Cer generation in the senescent phenotype. More specifically, downregulation of CerS2 by siRNA blocked the increase of VLC Cer (C24, C24:1, and C26:1) induced by SK1 knockdown and phenocopied the effects of FB1 on p21 expression. Taken together, these data show that targeting SK1 is a potential therapeutic strategy in cancer, enhancing oncogene-induced senescence through an increase of VLC Cer downstream of CerS2.Subject terms: Cancer metabolism, Senescence